Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
|Articles|December 4, 2017

US Clinical Investigator Experience

This data analysis takes a look at how much experience US clinical investigators have.

The Open Payments database provides invaluable information about the US clinical investigator terrain. The US government, through the Sunshine Act, requires that all payments to physicians by the pharmaceutical and medical instruments industries be reported in the Open Payments database. The reported details allow us to establish the actual number of US clinical trials in which an investigator has taken part. The last completed database release included data through December 31, 2016. We examine the three years for which complete data are available.

The concentration of clinical trial activity is clear. Less than a third, 29%, of clinical investigators took part in an industry sponsored study for the first time in 2016. They may, of course, have taken part in studies before January 1, 2014. However, for the three years covered by these industry data, these investigators appear for the first time in 2016.

The large number of investigators who average less than two clinical trials a year is noteworthy. Three quarters of the total active US clinical investigator pool fall within this category. Research in a large number of fields demonstrates the value of accumulated learning. This may be expressed in terms such as moving down the experience curve, or simple trial and error. However, a large number of current US clinical investigators have limited clinical trial experience.

 

Total Number of US Clinical Trials per Investigator (2014-2016)*

1

2  to 3

4 to 5

6 to 10

11 to 15

More than 15

29%

28%

19%

14%

7%

3%

 
 
 
 
 
 

*for active Clinical Investigators in 2016

 


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
The Human Side of Clinical Trials: Why Fuzzy Mental Models Undermine Clinical Trial Execution
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.